Fast-Tracking NDA Approval For A Novel Compound To Treat Infections

View highlights of the successful technology transfer and manufacturing scale-up of a novel therapy designed to treat drug-resistant infections. The program required rapid progression from late-stage clinical supply to registration batch manufacturing, followed by regulatory submission and commercial readiness. A key challenge was executing a high-risk technology transfer within strict timelines and limited material availability, requiring a first-time-right approach. Through detailed process understanding, risk assessment, and control strategy design, the manufacturing process was successfully transferred and scaled with minimal batches. The team also incorporated complex product requirements, including packaging, analytical testing, and stability studies, while ensuring compliance with stringent regulatory standards. Completion of registration batches and proactive process validation enabled submission and approval within a compressed timeline of less than two years.

This work demonstrates how effective technology transfer, integrated development, and robust quality systems can accelerate regulatory success and commercial manufacturing readiness.